DIGITAL HEALTH NEWS

Welcome to #1 Digital Health News Portal.

Not a subscriber yet?
Get breaking DIGITAL HEALTH NEWS straight to your inbox. Subscribe now, it's free!

Open Access Drug Development Tools Feature in New IMI Call for Proposals

Innovative Medicines InitiativeNew open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of the Call is over EUR 80 million. Half of this comes from the European Commission's Horizon 2020 programme and will fund the participation in the projects of universities, small and medium-sized companies, patient groups etc. The other half comes from large pharmaceutical companies and IMI Associated Partners, who do not receive EU funding through IMI but finance their own participation in our projects.

Open access tools for the genetics of disease - Many diseases have a genetic component, yet we lack the tools to study many of the genes behind diseases. This topic aims to develop a set of open access tools to facilitate the study around 1 000 of the 3 000 genes thought to be implicated in disease and that could be targeted by drugs. The results of the project will be made fully available to the scientific community by open access.

Optimising future obesity treatment - Obesity affects some 650 million people globally, placing them at greater risk of complications such as heart disease, diabetes and cancer to name a few. This topic aims to better understand obesity as a disease by identifying subgroups of people with obesity that will ultimately pave the way for better, more personalised prevention and lifestyle interventions, as well as treatments for obesity and its complications. The project will also focus on diabetes (both types 1 and 2) as examples of conditions that are influenced by obesity in a complex way.

Environmental impacts of medicines - Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). This topic will help to reduce the impact of medicines on the environment in three ways. Firstly, it will deliver tools to identify environmental risks associated with medicines under development. Secondly, it will prioritise which existing medicines (introduced before the ERA) should go through a tailored environmental assessment. Finally, it will create a publicly-available database to make environmental data on human medicinal products more transparent to all stakeholders.

Pierre Meulien, IMI Executive Director commented: "If we want to enjoy the benefits of the genomic revolution, we have to develop tools to study in detail the genes that influence our health. By taking an open access approach, the new topic launched as part of today's Call for proposals will maximise the impacts of its results by making it possible for researchers worldwide to access and use them in their own work."

For more information on IMI2 - Call 17, including the full Call text and details of how to apply, please visit:
http://www.imi.europa.eu/imi2-call-17

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Health Fabric and Sandwell Council Secur…

Digital health company Health Fabric is preparing to work with Sandwell Council after learning that it has secured support from The Healthy Ageing Challenge. The company will work with public health...

Philips Highlights AI-Powered Precision …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, showcases its award-winning AI-powered systems and solutions debuting at the European Congress of Radiology (ECR, July 13-17, Vienna...

Siemens Healthineers Accelerates and Imp…

Siemens Healthineers presents functionalities powered by Artificial Intelligence (AI) that accelerate and improve Magnetic Resonance Imaging (MRI). The quality of MR imaging is defined by the trade-off between scan time...

Using Technology to Support Primary Care

Opinion Article by Paul Bensley, Managing Director of Primary Care Cloud Telephony Specialist X-on. It is good to see the publication of this strategy [A plan for digital health and social...

Building the Right Foundations to Delive…

Opinion Article by Gary Birks, Gary Birks, General Manager, UK and Ireland, Orion Health. The latest strategy for health and care IT looks to build on what has been achieved over...

Two Leading CIOs Join the Highland Marke…

Two of the NHS' most dynamic chief information officers have joined Highland Marketing’s advisory board of NHS IT professionals and health tech industry experts. Ian Hogan, a CIO at the Northern...

A Machine Learning Model to Predict Immu…

Immunotherapy is a new cancer treatment that activates the body's immune system to fight against cancer cells without using chemotherapy or radiotherapy. It has fewer side effects than conventional anticancer...

Virtual Reality App Trial Shown to Reduc…

Results from a University of Otago, Christchurch trial suggest fresh hope for the estimated one-in-twelve people worldwide suffering from a fear of flying, needles, heights, spiders and dogs. The trial, led...

Teaching AI to Ask Clinical Questions

Physicians often query a patient's electronic health record for information that helps them make treatment decisions, but the cumbersome nature of these records hampers the process. Research has shown that...

MIT Engineers Develop Stickers that can …

Ultrasound imaging is a safe and noninvasive window into the body’s workings, providing clinicians with live images of a patient’s internal organs. To capture these images, trained technicians manipulate ultrasound...

AI Analyses Neuron Changes to Detect whe…

A research group from Nagoya University in Japan has developed an artificial intelligence (AI) for analyzing cell images that uses machine learning to predict the therapeutic effect of drugs. Called...

Patient Deterioration Predictor could Su…

An artificial intelligence-driven device that works to detect and predict hemodynamic instability may provide a more accurate picture of patient deterioration than traditional vital sign measurements, a Michigan Medicine study...